1. PAD Patients vs Post-ACS Patients:

3. Goals

4. Design and Rationale for EUCLID

5. EUCLID Clinical Trial Management

6. EUCLID: Baseline Characteristics

7. Kaplan-Meier Estimate of the Primary Endpoint

8. EUCLID: Efficacy Outcomes

9. EUCLID Event Rates

10. Safety Outcomes

11. PLATO Design

12. PLATO Primary Endpoint

13. PLATO PAD Subgroup

14. PEGASUS Design

15. PEGASUS Primary Endpoint

16. MACE With Ticagrelor by PAD at Baseline

17. Exploring the Discrepancy What Are the Lessons?

18. Exploring the Discrepancy CVP2C19 Exclusion

19. Exploring the Discrepancy 2 Active Drugs

20. Exploring the Discrepancy Different Population

21. Exploring the Discrepancy Comparison With PLATO

22. Exploring the Discrepancy Comparison With PEGASUS

23. CHARISMA: Primary Endpoint in Patients With Prior MI, Stroke, or Symptomatic PAD (Background Aspirin)

24. CAPRIE Clopidogrel vs Aspirin

25. EUCLID: Impact on ACS Patients?

26. Efficacy Outcomes: Stroke

27. Stroke Risk Reduction in EUCLID

28. SOCRATES Efficacy and Safety Outcomes

29. Stroke Risk With More Intensive Antiplatelet Therapy

30. Conclusion

31. Abbreviations

32. Abbreviations (cont)